top of page
NAFLDlogo-01_edited.png
Science Lab

The Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Program*

Massachusetts General Hospital

*Formerly known as NAFLD or "fatty liver"

MISSION
shutterstock_289976045.jpg

OUR MISSION 

To build an inclusive community dedicated to understanding the pathogenesis and treatment of MASLD and its complications, through innovative research, education, service, and excellence in patient care.

TEAM

OUR TEAM

The MGH MASLD Group is a diverse community of clinicians and investigators dedicated to enhancing the lives of our patients through research, clinical care, education, and service. 

shutterstock_1537303901.jpg

FATTY LIVER HAS A NEW NAME! 

Fatty liver disease, as we have come to know it, is the most common cause of chronic liver disease globally. As such, it was important for the global liver community to come to a consensus on the nomenclature and diagnostic criteria associated with the disease, to increase disease awareness and research. In June of 2023, leading liver disease experts from around the world announced the nomenclature change for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) to metabolic-dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), respectively. 

Since certain metabolic components have been increasingly associated with the disease, the consensus also included in the definition of MASLD the presence of at least 1 of 5 cardiometabolic risk factors. The new nomenclature, MASLD and MASH, allow for the incorporation of these metabolic components, while also removing previously included terminology that was exclusionary and potentially stigmatizing. The new overarching term to emcompass all variations of steatosis is steatotic liver disease (SLD)

The global consensus determined that patients who have no metabolic risk factors, and no known cause are to be classified as cryptogenic steatotic liver disease. In addition, a new category of SLD, called metabolic and alcohol related/associated liver disease (MetALD), was created to emcompass those with MASLD, who consume alcohol in quantities between 140-350 g/wk for women and 210-420 g/wk for men. 

LATEST
CONTACT

LATEST NEWS & EVENTS

New publication shows association between tobacco use and type 2 diabetes on risk of fibrosis in patients with MASLD. Link here: Tobacco Use, T2DM Have Additive Effect on Fibrosis Risk in MASLD - Mass General Advances in Motion


 
New NAFLD guidelines have been published. Link here: AASLD NAFLD Guidelines

Want more details?

We are always looking to expand our group and we welcome collaboration.

Cellphone

FOLLOW US

  • X
bottom of page